Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3010% below fair value
$7.97−0.34 (-4.09%)
Close on Nov 17, 2026Market cap $226.53MP/E –Yield –
Arcturus Therapeutics cash
Cash and short-term investments held at the end of each period.
Arcturus Therapeutics's cash was $191.48M at Jun 30, 2026. For fiscal 2025 it was $230.91M, down 21.4% from the year before. The highest annual figure on record is $463.00M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.91M | -21.4% |
| FY2024 | Dec 31, 2024 | $293.91M | +0.7% |
| FY2023 | Dec 31, 2023 | $292.01M | -25.9% |
| FY2022 | Dec 31, 2022 | $393.98M | +5.7% |
| FY2021 | Dec 31, 2021 | $372.57M | -19.5% |
| FY2020 | Dec 31, 2020 | $463.00M | +548.9% |
| FY2019 | Dec 31, 2019 | $71.35M | +93.8% |
| FY2018 | Dec 31, 2018 | $36.82M | +45.9% |
| FY2017 | Dec 31, 2017 | $25.24M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $191.48M | -2.5% |
| Q1 FY2026 | Mar 31, 2026 | $211.38M | -2.6% |
| Q4 FY2025 | Dec 31, 2025 | $230.91M | -21.4% |
| Q3 FY2025 | Sep 30, 2025 | $180.36M | -24.0% |
| Q2 FY2025 | Jun 30, 2025 | $196.47M | -24.5% |
| Q1 FY2025 | Mar 31, 2025 | $216.95M | -24.8% |
| Q4 FY2024 | Dec 31, 2024 | $293.91M | +0.7% |
| Q3 FY2024 | Sep 30, 2024 | $237.18M | -24.0% |
| Q2 FY2024 | Jun 30, 2024 | $260.33M | -19.5% |
| Q1 FY2024 | Mar 31, 2024 | $288.40M | -12.1% |
| Q4 FY2023 | Dec 31, 2023 | $292.01M | -25.9% |
| Q3 FY2023 | Sep 30, 2023 | $311.92M | +31.2% |
| Q2 FY2023 | Jun 30, 2023 | $323.47M | +14.1% |
| Q1 FY2023 | Mar 31, 2023 | $327.94M | +2.6% |
| Q4 FY2022 | Dec 31, 2022 | $393.98M | +5.7% |
| Q3 FY2022 | Sep 30, 2022 | $237.68M | -42.6% |
| Q2 FY2022 | Jun 30, 2022 | $283.49M | -34.6% |
| Q1 FY2022 | Mar 31, 2022 | $319.68M | -31.5% |
| Q4 FY2021 | Dec 31, 2021 | $372.57M | -19.5% |
| Q3 FY2021 | Sep 30, 2021 | $413.88M | +34.8% |
| Q2 FY2021 | Jun 30, 2021 | $433.57M | +218.5% |
| Q1 FY2021 | Mar 31, 2021 | $466.84M | +685.0% |
| Q4 FY2020 | Dec 31, 2020 | $463.00M | +548.9% |
| Q3 FY2020 | Sep 30, 2020 | $307.02M | +313.9% |
| Q2 FY2020 | Jun 30, 2020 | $136.11M | +143.8% |
| Q1 FY2020 | Mar 31, 2020 | $59.47M | +90.5% |
| Q4 FY2019 | Dec 31, 2019 | $71.35M | +93.8% |
| Q3 FY2019 | Sep 30, 2019 | $74.17M | +144.5% |
| Q2 FY2019 | Jun 30, 2019 | $55.84M | +90.4% |
| Q1 FY2019 | Mar 31, 2019 | $31.22M | +23.7% |
| Q4 FY2018 | Dec 31, 2018 | $36.82M | – |
| Q3 FY2018 | Sep 30, 2018 | $30.33M | – |
| Q2 FY2018 | Jun 30, 2018 | $29.32M | – |
| Q4 FY2017 | Dec 31, 2017 | $25.24M | – |
See a number that looks wrong?